跳至主要内容
临床试验/KCT0001225
KCT0001225进行中(未招募)未知

The clinical study for the evaluation of the efficacy and safety of YY-312 on reducing body weight and body fat mass of obese Korean. : a 12 weeks, randomized, double-blind, placebo-controlled clinical trial

Yuyu Phama0 个研究点目标入组 60 人开始时间: 待定最近更新:
适应症

试验速览

阶段
未知
状态
进行中(未招募)
发起方
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional Study

入排标准

年龄范围
19(Year) 至 60(Year)(—)
性别
All

入选标准

  • 1) Male and female subjects between 19-60years of age inclusive.
  • 2) BMI of 25.0 - 30.0kg/m2
  • 3) Evidense of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the trial

排除标准

  • 1) Subjects with systolicBP = 160 mmHg or diastolicBP = 100 mmHg and also taking a beta blocker or a hydragogue
  • 2) Subjects with diabetes(use of hypoglycemic agent or insulin)or fasting blood glucose = 126 mg/dL or random blood glucose = 200 mg/dL
  • 3) Subjects with endocrinopathy or abnormal screening TSH(Thyroid-Stimulating Hormone) value(=0.1uU/ml or =10 uU/ml)
  • 4) Subjects with hyperlipidemia) (fasting triglycerides > 600mg/dl)
  • 5) Serum AST(aminotransferse)/ALT(alanine amintransferse) = 3 times the upper limit of normal
  • 6) Serum creatinine = 1.5 times the upper limit of normal
  • 7) Use of prescription drugs or supplements known to alter body weight or appetite, antidepressants, oral contraceptive, steroid, female sex hormon
  • 8) Subjects with taking drugs that can affect the body weight within the 3 months
  • 9) Subjects with clinically significant cardiovascular disease within the 6 months prior to screening
  • 10) Subjects who change weight more than 4kg within 4 months
  • 11) Subjects with pancreatopathy
  • 12) Subjects with chronic malabsorption syndrome or bile secretion disorder
  • 13) Subjects with undergoing gastrointestinal operation for reducing boy weight
  • 14) Subjects with postoperative intestinal adhesion
  • 15) Subjects with a history of cancer and intervention within the 5 years prior to screening
  • 16) Subjects with a history of CNS(central nervous system) disorder(depressive disorder, schizophrenia, alcoholism, drug addiction)
  • 17) Subjects with heart disease, kidney disease, liver disease, lung disease and cerebrovascular disease
  • 18) Subjects with gallbladder diseases, gastrointestinal diseases, gout and porphyria
  • 19) Subjects with asthma and allergic disease
  • 20) Subjects with bulimia and abuse of relievers
  • 21) Women of childbearing age who are disagreed with effective contraceptions in the clinical trial period
  • 22) Woman who are pregnant or lactating
  • 23) Participation in any clinical trial within the 1 month prior to screening.
  • 24) Subjects who could affect preclude evaluation of response in the opinion investigator

研究者

发起方
Yuyu Phama

相似试验

The clinical study for the evaluation of the... | 临床试验